Clinical Trial Update: RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for rivaroxaban in stroke patients with antiphospholipid syndrome and related autoimmune conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome
• Brain Ischemia
• Stroke
• Systemic Lupus Erythematosus

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University College, London | Conditions: Antiphospholipid Syndrome, Systemic Lupus Erythematosus | Phase 2 | Status: UNKNOWN